JP2003530369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530369A5 JP2003530369A5 JP2001575212A JP2001575212A JP2003530369A5 JP 2003530369 A5 JP2003530369 A5 JP 2003530369A5 JP 2001575212 A JP2001575212 A JP 2001575212A JP 2001575212 A JP2001575212 A JP 2001575212A JP 2003530369 A5 JP2003530369 A5 JP 2003530369A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- functional
- agent according
- gene
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 19
- 241000700605 Viruses Species 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 101150027427 ICP4 gene Proteins 0.000 description 4
- 101710130522 mRNA export factor Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 2
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 2
- 101150090364 ICP0 gene Proteins 0.000 description 2
- 101150076998 ICP34.5 gene Proteins 0.000 description 2
- 108700002232 Immediate-Early Genes Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000037952 HSV-1 infection Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 101150050057 UL43 gene Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0009079.5 | 2000-04-12 | ||
| GBGB0009079.5A GB0009079D0 (en) | 2000-04-12 | 2000-04-12 | Herpes viruses for immune modulation |
| PCT/GB2001/001666 WO2001077358A2 (en) | 2000-04-12 | 2001-04-12 | Herpes viruses for immune modulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012125645A Division JP5543528B2 (ja) | 2000-04-12 | 2012-06-01 | 免疫モジュレーション用のヘルペスウイルス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530369A JP2003530369A (ja) | 2003-10-14 |
| JP2003530369A5 true JP2003530369A5 (enExample) | 2008-03-21 |
Family
ID=9889816
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001575212A Pending JP2003530369A (ja) | 2000-04-12 | 2001-04-12 | 免疫モジュレーション用のヘルペスウイルス |
| JP2012125645A Expired - Fee Related JP5543528B2 (ja) | 2000-04-12 | 2012-06-01 | 免疫モジュレーション用のヘルペスウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012125645A Expired - Fee Related JP5543528B2 (ja) | 2000-04-12 | 2012-06-01 | 免疫モジュレーション用のヘルペスウイルス |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1272652B1 (enExample) |
| JP (2) | JP2003530369A (enExample) |
| KR (1) | KR100805771B1 (enExample) |
| CN (1) | CN100351385C (enExample) |
| AT (1) | ATE278795T1 (enExample) |
| AU (1) | AU783395B2 (enExample) |
| BR (1) | BR0109928A (enExample) |
| CA (1) | CA2405458C (enExample) |
| DE (1) | DE60106222T2 (enExample) |
| DK (1) | DK1272652T3 (enExample) |
| ES (1) | ES2230291T3 (enExample) |
| GB (2) | GB0009079D0 (enExample) |
| HK (1) | HK1048136B (enExample) |
| IL (2) | IL152055A0 (enExample) |
| MX (1) | MXPA02010074A (enExample) |
| PT (1) | PT1272652E (enExample) |
| WO (1) | WO2001077358A2 (enExample) |
| ZA (1) | ZA200207920B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7063851B2 (en) | 2000-04-12 | 2006-06-20 | Biovex Limited | Herpes viruses for immune modulation |
| JP2004099584A (ja) * | 2002-05-02 | 2004-04-02 | Keio Gijuku | Ｈｓｖを用いた抗腫瘍剤 |
| US7695725B2 (en) * | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
| GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| WO2007016239A2 (en) * | 2005-07-29 | 2007-02-08 | President And Fellows Of Harvard College | Herpes simplex virus mutant and uses therefore |
| CN102146418B (zh) * | 2010-02-09 | 2014-01-15 | 武汉滨会生物科技有限公司 | 重组ⅱ型单纯疱疹病毒载体及其制备方法、重组病毒、药物组合物及应用 |
| CN105219739A (zh) * | 2015-09-21 | 2016-01-06 | 北京神源德生物科技有限公司 | 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用 |
| CN105219738A (zh) * | 2015-09-21 | 2016-01-06 | 北京神源德生物科技有限公司 | 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用 |
| JP7075653B2 (ja) * | 2018-02-06 | 2022-05-26 | 学校法人福岡大学 | αヘルペスウイルス感染を処置する方法及び医薬組成物 |
| CN109161561A (zh) * | 2018-08-09 | 2019-01-08 | 湖北科技学院 | 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法 |
| KR20250024845A (ko) * | 2022-08-05 | 2025-02-19 | 임비라 바이오파마수티컬스 컴퍼니 리미티드 | 복제 결함형 헤르페스 심플렉스 바이러스 1형바이러스 백신 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763217A (en) * | 1993-11-10 | 1998-06-09 | University Of British Columbia | Method of using, process of preparing and composition comprising recombinant herpesvirus vectors |
| GB9615794D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
| US5998174A (en) * | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| GB9801930D0 (en) * | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| GB9810904D0 (en) * | 1998-05-20 | 1998-07-22 | Univ London | Mutant herpes simplex viruses and uses thereof |
| GB9816781D0 (en) * | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
-
2000
- 2000-04-12 GB GBGB0009079.5A patent/GB0009079D0/en not_active Ceased
-
2001
- 2001-04-12 JP JP2001575212A patent/JP2003530369A/ja active Pending
- 2001-04-12 CN CNB018109330A patent/CN100351385C/zh not_active Expired - Fee Related
- 2001-04-12 KR KR1020027013753A patent/KR100805771B1/ko not_active Expired - Fee Related
- 2001-04-12 GB GB0224000A patent/GB2376687B/en not_active Expired - Fee Related
- 2001-04-12 DK DK01919668T patent/DK1272652T3/da active
- 2001-04-12 WO PCT/GB2001/001666 patent/WO2001077358A2/en not_active Ceased
- 2001-04-12 MX MXPA02010074A patent/MXPA02010074A/es active IP Right Grant
- 2001-04-12 AT AT01919668T patent/ATE278795T1/de active
- 2001-04-12 IL IL15205501A patent/IL152055A0/xx unknown
- 2001-04-12 HK HK03100195.0A patent/HK1048136B/zh not_active IP Right Cessation
- 2001-04-12 DE DE60106222T patent/DE60106222T2/de not_active Expired - Lifetime
- 2001-04-12 AU AU46728/01A patent/AU783395B2/en not_active Ceased
- 2001-04-12 PT PT01919668T patent/PT1272652E/pt unknown
- 2001-04-12 BR BR0109928-0A patent/BR0109928A/pt not_active IP Right Cessation
- 2001-04-12 EP EP01919668A patent/EP1272652B1/en not_active Expired - Lifetime
- 2001-04-12 CA CA2405458A patent/CA2405458C/en not_active Expired - Fee Related
- 2001-04-12 ES ES01919668T patent/ES2230291T3/es not_active Expired - Lifetime
-
2002
- 2002-10-01 IL IL152055A patent/IL152055A/en not_active IP Right Cessation
- 2002-10-02 ZA ZA200207920A patent/ZA200207920B/en unknown
-
2012
- 2012-06-01 JP JP2012125645A patent/JP5543528B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003502008A5 (enExample) | ||
| Whitley et al. | Herpes simplex viruses: is a vaccine tenable? | |
| Krishnan et al. | Developments in vaccination for herpes simplex virus | |
| Truong et al. | Mechanisms of immune control of mucosal HSV infection: A guide to rational vaccine design | |
| Herrlinger et al. | Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector | |
| Shin et al. | Generating protective immunity against genital herpes | |
| JP2003530369A5 (enExample) | ||
| CA2398335A1 (en) | Herpes virus strains | |
| JP2003520044A5 (enExample) | ||
| Frazer | The role of the immune system in anogenital human papillomavirus. | |
| Su et al. | An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application | |
| KR101747987B1 (ko) | 단순 헤르페스 바이러스 백신 | |
| Stanfield et al. | Herpes simplex vaccines: prospects of live-attenuated HSV vaccines to combat genital and ocular infections | |
| WO2014063601A1 (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
| Uchida et al. | Oncolytic herpes simplex virus vectors fully retargeted to tumor-associated antigens | |
| Pollara et al. | The host response to herpes simplex virus infection | |
| Gyotoku et al. | Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10ΔPK | |
| CA2405458A1 (en) | Herpes viruses for immune modulation | |
| Osorio et al. | Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines | |
| Chung et al. | The ongoing pursuit of a prophylactic HSV vaccine | |
| Ghiasi et al. | Overexpression of interleukin-2 by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunity | |
| Kim et al. | Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer | |
| Ramachandran et al. | Potential prophylactic and therapeutic vaccines for HSV infections | |
| US20080089910A1 (en) | Attenuated Herpes Simplex Virus Type-2, Vectors Thereof and Immunogenic Compositions Thereof | |
| HALFORD et al. | Immunization with HSV-1 antigen rapidly protects against HSV-1-induced encephalitis and is IFN-γ independent |